Law Daily Report

Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results To Test Whether A Dementia D...

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 33 sec. here
  • 12 min. at publisher
  • 📊 Quality Score:
  • News: 52%
  • Publisher: 71%

Chemotherapy News

Dementia,Donepezil,Alzheimer's Disease

Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.

May 20 2024Atrium Health Wake Forest Baptist

The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.The researchers enrolled 276 breast cancer survivors from community oncology practices affiliated with the National Cancer Institute Community Oncology Research Program , a national network that brings cancer clinical trials and care delivery studies to communities.

The participants were assigned to either receive 5-10 mg of donepezil, taken once a day for 24 weeks, or placebo." Related StoriesCognitive assessments were conducted before treatment, at 12 weeks and at end of treatment.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in LAW

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammationChronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.
Source: NewsMedical - 🏆 19. / 71 Read more »